Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: A Q&A with an Extraordinary Healer
June 30, 2009 – Kathy LaTour
Web Exclusive: Types of Kidney Cancer
June 25, 2009 – The American Cancer Society
Web Exclusive: Helpful Advice
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Developing a Strategy
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Searching for New Targets
June 23, 2009 – Elizabeth Whittington
Web Exclusive: When Survivors Should Exercise Caution
June 22, 2009 – Lena Huang
Web Exclusive: Fertility Guidelines Not Meeting Needs of Patients
June 22, 2009 – Elizabeth Whittington
Web Exclusive: A Peaceful Spirit
June 18, 2009 – Toby Bressler, RN, BSN, OCN
Web Exclusive: The Voice on the Other End of the Phone
June 18, 2009 – Dianne Ericson
Excerpt: Stronger
June 17, 2009 – Natalie Flechsig
Web Exclusive: An Infection Out of Nowhere
June 16, 2009
Web Exclusive: Solving a Medical Mystery
June 16, 2009 – Debu Tripathy, MD
Web Exclusive: Clinical Trials for CUP
June 16, 2009
Childhood Cancer Survivorship Programs
June 16, 2009
Chicken Soup for the Soul: The Cancer Book
June 15, 2009 – Kathy LaTour
Improved Care Needed for Patients Receiving Heart-Toxic Drugs
June 15, 2009 – Melissa Weber
Cancer Research Receives Infusion of Federal Funds
June 15, 2009 – Lacey Meyer
Resources
June 09, 2009
P.S. A Word About Implants & Some Unanswered Questions
June 09, 2009 – Kathy LaTour
How to Find a Cancer Trainer
June 09, 2009 – Lena Huang
Smarter Trials for Smarter Drugs
June 09, 2009 – Laura Beil
Sticker Shock
June 09, 2009 – Laura Beil
Resources
June 09, 2009
From Cancer Warrior to Basketball Player
June 09, 2009 – Deirdre Carey
Taking a Closer Look
June 09, 2009 – Karen Patterson
Surgical Strategies
June 09, 2009 – Karen Patterson
Hair Loss Snapshot
June 09, 2009 – Lacey Meyer
Weighing the Techniques
June 09, 2009 – Charlotte Huff
What About CUP Patients?
June 09, 2009 – Katy Human
Hard Times
June 09, 2009 – Joanne Kenen
Reconstruction Do-Overs
June 09, 2009 – Kathy LaTour
Fighting Fatigue
June 09, 2009 – Lena Huang
Disjointed Custody
June 09, 2009 – Charlotte Huff
No I.D.
June 09, 2009 – Katy Human
ASCO Updates
June 09, 2009 – Staff Reports
Interventions Needed to Get Survivors Moving
June 09, 2009 – Lena Huang
The Financial Advocate
June 09, 2009 – Kathy LaTour
Ovarian Cancer Survivors Course
June 09, 2009
Q & A: Prostate Cancer Screening
June 09, 2009 – Len Lichtenfeld, MD
www.armyofwomen.org
June 09, 2009 – Elizabeth Whittington
With a Friend Like Will Ferrell...
June 09, 2009 – Lacey Meyer
Program Keeps Tabs on Childhood Cancer Survivors
June 09, 2009 – Lacey Meyer
Revisiting the Seasons of Survival
June 09, 2009 – Kenneth D. Miller, MD
Prostate, Brain & Kidney Cancers
June 09, 2009 – Elizabeth Whittington
A Life Beyond Cancer
June 09, 2009 – Renée La Forest
Good Grilling
June 09, 2009 – Lena Huang
Medical Devices Face Stricter Regulations
June 09, 2009 – Jo Cavallo
All Is Not Lost
June 09, 2009 – Lacey Meyer
Letters from Our Readers
June 09, 2009
Message from the Editor
June 09, 2009 – Debu Tripathy, MD
Targeted Therapy: Hope or Hype?
June 09, 2009 – Laura Beil
Conquering Cancer & the Classroom
June 09, 2009 – Scott Williams
Reining in Renal Cancer
June 09, 2009 – Karen Patterson
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
July 09, 2009
Web Exclusive: A Q&A with an Extraordinary Healer
June 30, 2009 – Kathy LaTour
Web Exclusive: Types of Kidney Cancer
June 25, 2009 – The American Cancer Society
Web Exclusive: Helpful Advice
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Developing a Strategy
June 25, 2009 – Elizabeth Whittington
Web Exclusive: Searching for New Targets
June 23, 2009 – Elizabeth Whittington
Web Exclusive: When Survivors Should Exercise Caution
June 22, 2009 – Lena Huang
Web Exclusive: Fertility Guidelines Not Meeting Needs of Patients
June 22, 2009 – Elizabeth Whittington
Web Exclusive: A Peaceful Spirit
June 18, 2009 – Toby Bressler, RN, BSN, OCN
Web Exclusive: The Voice on the Other End of the Phone
June 18, 2009 – Dianne Ericson
Excerpt: Stronger
June 17, 2009 – Natalie Flechsig
Web Exclusive: An Infection Out of Nowhere
June 16, 2009
Web Exclusive: Solving a Medical Mystery
June 16, 2009 – Debu Tripathy, MD
Web Exclusive: Clinical Trials for CUP
June 16, 2009
Childhood Cancer Survivorship Programs
June 16, 2009
Chicken Soup for the Soul: The Cancer Book
June 15, 2009 – Kathy LaTour
Improved Care Needed for Patients Receiving Heart-Toxic Drugs
June 15, 2009 – Melissa Weber
Cancer Research Receives Infusion of Federal Funds
June 15, 2009 – Lacey Meyer
Resources
June 09, 2009
P.S. A Word About Implants & Some Unanswered Questions
June 09, 2009 – Kathy LaTour
How to Find a Cancer Trainer
June 09, 2009 – Lena Huang
Smarter Trials for Smarter Drugs
June 09, 2009 – Laura Beil
Sticker Shock
June 09, 2009 – Laura Beil
Resources
June 09, 2009
From Cancer Warrior to Basketball Player
June 09, 2009 – Deirdre Carey
Taking a Closer Look
June 09, 2009 – Karen Patterson
Surgical Strategies
June 09, 2009 – Karen Patterson
Hair Loss Snapshot
June 09, 2009 – Lacey Meyer
Weighing the Techniques
June 09, 2009 – Charlotte Huff
What About CUP Patients?
June 09, 2009 – Katy Human
Hard Times
June 09, 2009 – Joanne Kenen
Reconstruction Do-Overs
June 09, 2009 – Kathy LaTour
Fighting Fatigue
June 09, 2009 – Lena Huang
Disjointed Custody
June 09, 2009 – Charlotte Huff
No I.D.
June 09, 2009 – Katy Human
Currently Viewing
ASCO Updates
June 09, 2009 – Staff Reports
The Financial Advocate
June 09, 2009 – Kathy LaTour
Ovarian Cancer Survivors Course
June 09, 2009
Q & A: Prostate Cancer Screening
June 09, 2009 – Len Lichtenfeld, MD
www.armyofwomen.org
June 09, 2009 – Elizabeth Whittington
With a Friend Like Will Ferrell...
June 09, 2009 – Lacey Meyer
Program Keeps Tabs on Childhood Cancer Survivors
June 09, 2009 – Lacey Meyer
Revisiting the Seasons of Survival
June 09, 2009 – Kenneth D. Miller, MD
Prostate, Brain & Kidney Cancers
June 09, 2009 – Elizabeth Whittington
A Life Beyond Cancer
June 09, 2009 – Renée La Forest
Good Grilling
June 09, 2009 – Lena Huang
Medical Devices Face Stricter Regulations
June 09, 2009 – Jo Cavallo
All Is Not Lost
June 09, 2009 – Lacey Meyer
Letters from Our Readers
June 09, 2009
Message from the Editor
June 09, 2009 – Debu Tripathy, MD
Targeted Therapy: Hope or Hype?
June 09, 2009 – Laura Beil
Conquering Cancer & the Classroom
June 09, 2009 – Scott Williams
Reining in Renal Cancer
June 09, 2009 – Karen Patterson

ASCO Updates

News from the 2009 annual meeting of the American Society of Clinical Oncology.

BY Staff Reports
PUBLISHED June 09, 2009

The annual meeting of the American Society of Clinical Oncology was held in Orlando from May 29 to June 2. The gathering attracted 30,000 cancer researchers, physicians, and representatives from pharmaceutical and biotechnology industries to learn the latest in cancer care, treatment, and prevention. Details can be found at www.asco.org or ASCO’s patient website, www.cancer.net.

A new class of drugs called PARP inhibitors is getting some serious attention after a study in metastatic triple-negative breast cancer patients found that the agent BSI-201 significantly improved survival.

A phase II study randomly assigned 116 patients to receive chemotherapy (Gemzar [gemcitabine] and carboplatin) with or without intravenous BSI-201. For patients receiving the experimental agent, progression-free survival (the time before the tumor progressed) reached 6.9 months, compared with 3.3 months for the chemotherapy-alone group. Overall survival hit 9.2 months for the BSI-201 arm versus 5.7 months for patients not receiving the drug. Side effects were similar between the two groups, the most common of which were low blood counts.

A separate phase II study tested a different PARP inhibitor called olaparib as a single agent in patients with advanced breast cancer who have BRCA1 or BRCA2 mutations, a genetic alteration that predisposes a carrier to breast and ovarian cancers. In this single-arm trial, 11 of the 27 patients receiving the higher of the two doses used in the study had their tumors shrink by at least half. Side effects of the oral agent included mild nausea and fatigue.

PARP is an enzyme used by cancer cells to repair DNA damage—specifically the damage caused by chemotherapy. By inhibiting PARP, the cancer cells are more susceptible to the effects of treatment. PARP inhibitors are especially beneficial in patients who have deficient DNA repair systems, as is the case for those  with mutations in BRCA1 or BRCA2.

A phase III study of BSI-201 in metastatic triple-negative breast cancer will launch at the end of June, said researchers.

An international phase III trial found the investigational lung cancer drug, Zactima (vandetanib), significantly slowed the time a patient’s advanced lung cancer progressed. The trial, which included nearly 1,400 patients who progressed on prior therapy, compared Taxotere (docetaxel) in combination with either placebo or Zactima.

While the data do not show an overall survival advantage, patients on the Zactima arm had a median progression-free survival of 17.3 weeks compared with 14 weeks with Taxotere alone. Zactima works by blocking both vascular endothelial growth factor, which is instrumental in blood vessel growth to the tumor, and the epidermal growth factor receptor, a protein that spurs malignant cell growth.

Common side effects with Zactima are diarrhea, rash, and neutropenia, which can increase the risk of infection. With the progression-free survival benefit demonstrated, AstraZeneca, the drug’s manufacturer, is planning to submit the drug for Food and Drug Administration approval in the coming months. The drug is also being tested in thyroid cancer.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence. The offenders in the study—Paxil (paroxetine), Prozac (fluoxetine), and Zoloft (sertraline)—are part of a class of drugs that inhibit CYP2D6, an enzyme that converts tamoxifen to its active form.

A U.S study found that after two years, 7.5 percent of women who took only tamoxifen had a recurrence, compared with 16 percent who took Paxil, Prozac, or Zoloft—drugs considered to be the most potent CYP2D6 inhibitors. That difference translates to a 120 percent increase in the risk of breast cancer recurrence. Patients taking the so-called weaker antidepressants, Celexa (citalopram), Lexapro (escitalopram), and Luvox (fluvoxamine), did not have an increased risk of recurrence.

However, a Dutch study presented at the meeting did not find that simultaneous use was unsafe, most likely because of the small number of patients in the study who took both drugs, said Julie Gralow, MD, of the Seattle Cancer Care Alliance, at a press briefing. (Gralow was not involved in either study.) The Dutch trial included less than half the number of patients in the U.S. study who took the drugs concurrently—150 versus 353 women. Other drugs to treat depression and hot flashes that do not inhibit CYP2D6 should be considered for tamoxifen patients, said Gralow.

The breast cancer drug Herceptin (trastuzumab) extends survival in certain gastric cancer patients by almost three months, according to a phase III international study.

Because research has shown that about 20 percent of gastric tumors overexpress HER2, investigators randomly assigned 594 patients with locally advanced, recurrent, or metastatic HER2-positive gastric cancer to receive chemotherapy (5-FU or Xeloda [capecitabine] and cisplatin) with or without Herceptin. Patients receiving Herceptin had a median overall survival of 13.8 months compared with 11.1 months in the chemotherapy-alone arm. For patients with the highest levels of HER2, median survival reached 16 months. Side effects were similar between the two arms, with no increased risk for heart damage, an effect sometimes seen with Herceptin.

“Based on these data, we should offer patients the option of [HER2] testing, and if they are HER2-positive … we should then offer these patients Herceptin,” said lead researcher Eric Van Cutsem, MD, PhD, of the University Hospital Gasthuisberg in Belgium, at a press briefing. 

The Food and Drug Administration approved Herceptin more than a decade ago for HER2-positive breast cancer. Roche, which markets Herceptin internationally, said in a statement that it plans to file the drug for approval in advanced HER2-positive gastric cancer.

While follicular lymphoma frequently responds to chemotherapy and can have a long course, the disease is considered incurable because it almost always recurs. Researchers of a lymphoma trial hope that BiovaxID, a personalized vaccine, could help delay those recurrences. 

The study included 117 patients who experienced at least a six-month remission after chemotherapy, and retained that remission until receiving either BiovaxID or a control vaccine. Each patient randomized to the BiovaxID arm was given a series of injections of a vaccine developed from their own cancer cells, making it a specialized targeted drug against the individual’s malignant B cells. After a median of nearly five years follow-up, BiovaxID improved cancer-free survival by 47 percent, delaying recurrence for more than a year, from 30.6 months to 44.2 months, when compared with the control vaccine. No major differences in side effects occurred between the two arms. 

Researchers stressed the need for future studies, including combining the vaccine with targeted drugs such as Rituxan (rituximab), an agent that is now a standard of care for lymphoma.

Results from an international study challenge current practice of screening for ovarian cancer relapse. Currently, survivors undergo quarterly monitoring of CA-125, a protein that is predictive of ovarian cancer relapse. With early detection of recurrence, patients often begin treatment before symptoms manifest. However, a study showing that early treatment does not improve overall survival may change that tradition.

For the first time, women can be offered informed choices after first-line chemotherapy. 

The study looked at 529 ovarian cancer survivors who were in remission but whose CA-125 levels began to rise. Researchers found that the group who received treatment at the time their levels increased did not live longer than the group who received treatment after the onset of symptoms (these patients did not have their levels made available to the physician or patient). Patients with early treatment received therapy about four to five months sooner than the delayed treatment group, but this did not result in improved survival. In addition, the quality of life was lower in the group who received quarterly CA-125 testing, presumably because of anxiety about the results and because this group was exposed to more types of chemotherapy and longer treatment.

“For the first time, women can be offered informed choices after first-line chemotherapy,” said presenter Gordon Rustin, MD, of Mount Vernon Cancer Centre, during the presentation. Because early treatment does not result in a survival advantage or a longer remission, Rustin told doctors there is no benefit from early recurrence detection with routine CA-125 testing.

Read more breaking news from ASCO at media.curetoday.com/htmlemail/CURExtra/ASCO2009.html.

Continue the conversation on CURE’s forum. >>
Talk about this article with other patients, caregivers, and advocates in the CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In